Products - Metabolic conditions | Topic | NICE

Showing 7 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 November 2025
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pegzilarginase for treating arginase-1 deficiency [ID4029]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venglustat for treating gangliosidoses in people 2 years and over ID 6358
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC